To Determine the Clinical Efficacy of COVID Vaccine in Post Vaccinated Individuals with Severe Pneumonia in Preventing ICU Mortality in a COVID Designated Tertiary Care Centre: A Retrospective Study

Bhavani Vaidyanathan*, Sangeeta Dhanger, Joseph Raajesh, Ravindra Bhat, Pratheeba Natrajan, Deepak Paulose, Ravindran Remadevi

Department of Anaesthesiology, Indiragandhi Medical College and Research Institute Puducherry, India.

ABSTRACT

Background: The "Severe Acute Respiratory Syndrome Coronavirus 2 disease has caused globally a challenging and threatening pandemic (COVID-19), with massive health and economic losses [1]. In India national vaccination campaigns kick started officially on January 16, 2021, and the vaccines were prioritized for frontline workers and susceptible groups. Individual vaccination can prevent or minimise a number of outcomes, including lab confirmed infection, symptomatic illness, infectivity rate, or a combination of these [2-3]. India had initially approved two vaccines under the trade name Covishield and Covaxin against COVID.

Aim: Demonstrate the efficacy of a single / two -dose schedule of COVID vaccine in the prevention of ICU mortality.

Methods: In this retrospective study, we included all COVID 19 confirmed patients who were admitted in covid designated ICU from March 15 to July 31 2021. Demographic, clinical, laboratory and radiological data were collected from all patients received in ICU. Primary outcome was to assess the mortality outcome in vaccinated COVID patients. Secondary outcome measured were to find an association between severity of the pneumonia and comorbidities, PaO2/Fio2 ratio, Neutrophil lymphocyte ratio, D dimer and CT severity score.

Results: 319 patients were enrolled in the study. 252 patients were not vaccinated.59 had received the first dose and 8 patients had received both the doses. The mortality among vaccinated patients were less compared to nonvaccinated and significant (p value 0.030). Mortality among single and double dose vaccinated patients couldn’t be made out because only 8 patients had received both the doses. Among the demographic profile, difference in age between vaccinated and unvaccinated was statistically significant. (64.39 ±11.916/ 54.18±14.124 p<.001. Among comorbidities hypertension, diabetes, obesity was associated with significant mortality. Admission saturation and mean PaO2/Fio2 ratio were high among vaccinated and significant. Neutrophil lymphocyte ratio, D dimer CT severity score were high among non vaccinated compared to vaccinated. There is no difference in mode of oxygen delivery in both vaccinated and non vaccinated patient. Days of ICU stayal was less among vaccinated.

Conclusion: Effectiveness of vaccine against SARS-CoV-2 infection after the first dose of immunisation is convincingly evident. However second dose of immunization should be continued to attain total protection.
The global COVID pandemic has ravaged thousands of lives and disrupted the lives of billions of people. Drug controller of India had approved use of two vaccines Covishield and Covaxin, which helped in reducing the mortality and to get the pandemic under control. Covishield, manufactured and marketed by Serum Institute of India is a viral vector vaccine in which spike proteins are injected and it mounts a tolerable immune response to live virus. Covaxin manufactured by Bharat Biotech, uses an inactive dead virus that drafts an immune response [4-5].

Government of India started vaccine administration for COVID in January 2021. As of November 2021, around 1.21 billion doses had been administered, including first and second doses of the currently-approved vaccines. At least 80% of the eligible population received one dose, and number of fully vaccinated has exceeded those who have partially vaccinated.

The first phase of the vaccine coverage involved health and frontline workers. The next phase of the vaccine rollout covered all residents over the age of 60, and residents between the ages of 45 and 60 with comorbidities. Vaccine for general public started on March 1st 2021 for age 45 to 60 years with no comorbidities.

Methods

In this single centre retrospective study, all patients who had been received in COVID ICU from March 15 to July 31st 2021 were included in the study. After approval of institute ethical committee, we included all confirmed cases from March 15 to July 31. Cases were confirmed by RT-PCR and were analysed for demographic, clinical, laboratory and radiological data. Patient case sheets were accessed from medical record section. Patients with SpO2<94% on room air, a respiratory rate >30 breaths/min, PaO2/FiO2<300 mm Hg, or lung infiltrates >50%, rapid clinical deterioration were considered as severe COVID [6]. Patients with acute respiratory distress syndrome, cardiac dysfunction, thrombotic disease were considered as critically ill.

The aim of this study was to estimate the frequency of COVID-19 death in people who received at least one or two doses of vaccine. Sampling method used was non probability sampling. The inclusion criteria were all patients of age greater than 18, fifteen days post vaccination, with RT PCR positive requiring ICU admission. Exclusion criteria were ICU patients without COVID-19, COVID patients under 18 years of age, patients with mild to moderate symptoms, with no respiratory distress, no signs of pneumonia on lung radiography or tomography. All vaccinated patients treated in ICU received covishield vaccine. March 15th was taken as cut off because the vaccine drive for common public was started on March 1st. Vaccine efficiency is judged by its ability to protect against severe disease, and decrease the transmissibility in a community, as critical-care admissions poses the greatest burden on health-care systems.

Statistical analysis

All statistical analysis was performed with the SPSS version 20.0 (Statistical Package for the Social Sciences). The data were initially analysed for normality with Kolmogorov-Smirnov test. Baseline characteristics with continuous variables were presented as median with interquartile range (IQR) and categorical variables as number with percentage. Comparisons between continuous variables were tested by the Student t test and Mann-Whitney test based on variable distribution, and chi square test for categorical variables. A two-sided P value less than .05 was considered statistically significant.

Results

342 patients were received in ICU, finally 319 patients were enrolled for the study. Out of 23 dropouts few case sheets were incomplete and few patients died within 12 hours of admission. 252 patients were not vaccinated, 59 had received the first dose and 8 patients had received both the doses. (Figure 1) The mortality among vaccinated patients were less compared to nonvaccinated and significant P value 0.030. Mortality among single and double couldn’t be made out because only 8 patients had received both the doses. There was a definitive gender variability with male preponderance. (Males 217/Females 102 p value=0.055). There was a statistically significant difference in age between vaccinated and unvaccinated (64.39 ±11.916/54.18±14.124 (p<.001). There was a significant association of mortality with comorbidities such as hypertension, diabetes, and obesity. The admission saturation and PF ratio was high in vaccinated population. Neutrophil lymphocyte ratio, D dimer CT severity score were high among nonvaccinated compared to vaccinated. There is no difference in mode of oxygen delivery in both vaccinated and nonvaccinated patient. The length of hospital stay was less in vaccinated patients.
Discussion

COVID-19 is a life-threatening disease that can have long-term sequelae. As the virus has a tendency to mutate vaccine efficacy is complex in the case of SARS-CoV-2, where the fundamental understanding of the pathogen is still questionable. There might not be a single vaccine which will cover up all variants SARS-CoV-2. We need a methodical framework for assessing vaccine efficacy endpoints to draw constructive conclusion and comparison. All patients in our study were vaccinated with Covishield. There was a male preponderance and this was coinciding with the study of study of Docherty [7-9]. There was a statistically significant difference in age between vaccinated and unvaccinated. [64.39±11.916/ 54.18±14.124 (p<.001)] This finding is because phase 2 vaccination was started only for population above 60 and people with comorbidities. The mortality among vaccinated patients were less compared to non vaccinated and significant [10-13] (Table 1).

Table 1 - Association between vaccination status and mortality

| Vaccine status | Total |
|----------------|-------|
|                | No dose | Either 1 or 2 dose |
| Outcome        | Death   | 216           | 50            |
|                | Discharge | 36           | 17            |
| Total          | 252     | 67            |

Chi-square test; p value=0.030

There was a significant association of mortality with comorbidities such as diabetes (p=0.006), hypertension, (p=0.001) obesity (p=0.05). This finding was consistent with Chen et al9 that people with hypertension and cardiovascular disease formed a major chunk among non survivors than survivors. These findings suggested that COVID-19 has a preponderance towards elderly with chronic comorbidities due to fragile immune functions. Admission saturation and PaO2/FiO2 ratio was high among vaccinated and significant (spo2 83.79±12.355/PF ratio 118.30±60.079 among vaccinated and 79.56±15.97 /101.43±50.13 in nonvaccinated (p=.035/.04). Neutrophil lymphocyte ratio among nonvaccinated group (median: 47.56; interquartile range [IQR]: 24.71-69.70) was higher than that of vaccinated group (median: 8.12; IQR: 3.44-8.12; P <.001). These results suggest that high NLR at the time of admission is associated with high mortality among patients with COVID-19. The virus damages lymphocytes, and hampers immune function during the course of the disease [14-15].

D dimer was greater than 2000 among nonvaccinated compared to vaccinated and (p=.051). Serum D-dimer were higher in patients with severe COVID compared to those with non-severe forms. In our study D-dimer levels values were 3-fold higher in those with severe disease (median: 2.12 mg/L; IQR: 0.77–5.27 mg/L) than in those with-out (median: 0.61 mg/L; IQR: 0.25–1.28 mg/l p<0.003). Cytokine storm induced by SARS-CoV triggers coagulation cascade, resulting in thrombotic complications. Therefore, patients with increased D-dimer should be started on antithrombotic therapies [16-18].

34% among non-vaccinated had thrombocytopenia and 18 % among vaccinated had thrombocytopenia (p value=.042). None of the patient platelet count decreased to a level that caused bleeding. Panyang Xu had concised the causes of thrombocytopenia in patients with COVID-19 and proposed a mechanisms by which COVID-19 causes thrombocytopenia [19].

CT severity score was high among nonvaccinated compared to vaccinated (Table 2). The CT score of the
vaccinated patients was significantly lower compared to unvaccinated patients (median 3.5 v. 9.5 respectively p<.01). Severity of the CT score is lowered by vaccination and hence improves survival outcome of the patient. Non vaccinated patients with comorbidities have higher CT scores in comparison to the vaccinated patients with comorbidity. Available data suggest that the vaccinated patients have better outcomes in terms of survival than nonvaccinated patients [20]. There were no significant association between oxygen delivery mode and vaccine status. Most of the patients both vaccinated and nonvaccinated were on intermittent Non-invasive ventilation and non-rebreathing mask. (p=.06). There was a significant difference among vaccinated (8.55±3.21) and nonvaccinated (11.55±4.56) p<.041 in duration of ICU stay.

Table 2- CT score and vaccine status

| CT score  | No dose | Either 1 or 2 dose | Total |
|-----------|---------|-------------------|-------|
| Mild      | 2       | 3                 | 5     |
| Moderate  | 41      | 29                | 70    |
| Severe    | 197     | 35                | 232   |
| Total     | 240     | 67                | 307   |

The above results are very much promising and vaccinated people had less mortality. We have to use our precious time to vaccinate all eligible people with two doses. With children still unvaccinated and many adults yet to receive the second dose a mutant variant at this time will result in rapid transmission and high transmissibility in this population. Mutations becoming inevitable long-term preparations and strategic planning to live with covid pandemic is essential. India has been successful in vaccinating more than 100 crore vaccine doses but these are single dose and not complete two dose which could be effective in fighting the new strain.

**Limitations**

This study was conducted at a single-centre, and only one type of vaccine covishield was researched. Only patients with relatively severe COVID-19 pneumonia were hospitalized during this period. Moreover, all vaccinated patients were not hospitalised. Patients age less than 18 though positive were excluded. Post Vaccination seroconversion which is a surrogate marker for vaccine efficacy could not be done because of limited resources.

**Conclusion**

We conclude that single dose of covishield is effective against SARS-CoV-2 infection 14 days post vaccination with the first dose. Immunization with the second dose should be achieved to attain the total protection against Covid 19. With new variants and new waves of infection anticipated we should act quickly and efficiently to improve the vaccination drive. However, the risk of infection cannot be eliminated, highlighting the need for non-pharmaceutical interventions such as face mask, hand hygiene and social distancing.

**References**

[1] Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021; 384(5):403–16.

[2] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020; 383(27):2603–15.

[3] Kataria S, Sharma P, Deswal V, Kumar K, Singh M, Alam S, et al. A Real World Evaluation of the safety and immunogenicity of the Covishield vaccine, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombiant) in Health Care Workers (HCW) in National Capital Region (NCR) of India: A preliminary report. medRxiv. 2021; 2021.04.14.21255452.

[4] Kumar VM, Pandi-Perumal SR, Trakht I, Thyagarajan SP, Strategy for COVID-19 vaccination in India: the country with the second highest population and number of cases. npj Vaccines. 2021;6(1):1–7.

[5] Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020; 20(6):669-677.

[6] Clinical Spectrum | COVID-19 Treatment Guidelines . Available: https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum

[7] Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20 133 UK patients in hospital with COVID-19 using the ISARIC WHO clinical characterisation protocol: prospective observational cohort study. BMJ. 2020; 369:m1985.

[8] Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382(18):1708–
20.

[9] Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395(10223):507–13.

[10] Lopez Bernal J, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021; 373:n1088.

[11] Hyams C, Marlow R, Maseko Z, King J, Ward L, Fox K, et al. Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study. Lancet Infect Dis. 2021; 21(11):1539–48.

[12] Prendecki M, Willicombe M. Single-dose SARS-CoV-2 vaccination efficacy in the elderly. Lancet Infect Dis. 2021; 21(11):1474–5.

[13] Shrotri M, Krutikov M, Palmer T, Giddings R, Azmi B, Subbarao S, et al. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study. Lancet Infect Dis. 2021; 21(11):1529–38.

[14] Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323(11):1061–9.

[15] Yan X, Li F, Wang X, Yan J, Zhu F, Tang S, et al. Neutrophil to lymphocyte ratio as prognostic and predictive factor in patients with coronavirus disease 2019: A retrospective cross-sectional study. J Med Virol. 2020; 92(11):2573-2581.

[16] Paliogiannis P, Mangoni AA, Dettori P, Nasrallah GK, Pintus G, Zinellu A. D-dimer concentrations and covid-19 severity: A systematic review and meta-analysis. Front Public Health. 2020; 8:1–7.

[17] Olson JD. D-dimer: An Overview of Hemostasis and Fibrinolysis, Assays, and Clinical Applications. Adv Clin Chem. 2015; 69:1–46.

[18] Liu B, Li M, Zhou Z, Guan X, Xiang Y. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? J Autoimmun. 2020; 111:102452.

[19] Xu P, Zhou Q, Xu J. Mechanism of thrombocytopenia in COVID-19 patients. Ann Hematol. 2020; 99(6):1205-8.

[20] Modi SD, Shah DS, Mundhra KS, Gandhi B, Shah R, Kagathara V, et al. Comparative Study of CT Severity Index and Outcome in Hospitalised Vaccinated and Non Vaccinated. J Radiol Clin Imaging. 2021;4(3):93–101.